Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • intron ARegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • INTRON ARegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)

Phase Distribution

Phase 2/3
1
50%
Phase 3
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2/3Combined phases
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 2/31 (50.0%)
Phase 31 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2_3

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

NCT03552549
completedphase_3

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)

NCT00221702

Clinical Trials (2)

Showing 2 of 2 trials
NCT03552549Phase 2/3

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Terminated
NCT00221702Phase 3

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)

Completed

All 2 trials loaded

Drug Details

Intervention Type
Varies by study
Total Trials
2